Latest News on AGIO

Financial News Based On Company


Advertisement
Advertisement

The Lynx1 Fund holds 472,606 shares in Agios Pharmaceuticals (AGIO), a 0.8% stake.

https://www.stocktitan.net/sec-filings/AGIO/schedule-13g-a-agios-pharmaceuticals-inc-amended-passive-investment-d-bc3b17a48f5b.html
Lynx1 Capital Management LP and Weston Nichols, through the Lynx1 Fund, reported beneficial ownership of 472,606 common shares in Agios Pharmaceuticals (AGIO), representing a 0.8% stake. Both reporting persons share voting and dispositive power over these shares. This information was disclosed in an amended Schedule 13G filing.

Morgan Stanley reports over 5% of Agios (AGIO), with no sole voting power.

https://www.stocktitan.net/sec-filings/AGIO/schedule-13g-agios-pharmaceuticals-inc-passive-investment-disclosure--ab60e27f6a3f.html
Morgan Stanley has reported a beneficial ownership of 3,431,830 shares, or 5.7%, of Agios Pharmaceuticals (AGIO) common stock as of September 30, 2026. The investment bank holds shared voting power over 3,431,285 shares and shared dispositive power over all 3,431,830 shares, but notably, it possesses no sole voting or dispositive power over these shares. This filing reflects the holdings of certain Morgan Stanley operating units and excludes other units whose ownership is disaggregated.

Novo Catching Up Agios In Sickle Cell With Etavopivat Filings

https://insights.citeline.com/scrip/therapeutic-category/blood-and-clotting/novo-catching-up-agios-in-sickle-cell-with-etavopivat-filings-UKCG2G6MH5C2NLPLDAY2VGJZBM/
Novo Nordisk has filed for approval of its oral pyruvate kinase-R (PKR) activator, etavopivat, for sickle cell disease (SCD) with both the FDA and EMA. This move positions Novo Nordisk in direct competition with Agios Pharmaceuticals, whose own candidate, mitapivat, recently experienced a delay in its FDA decision. The article highlights the intensifying race to market an oral PKR activator for SCD between the two pharmaceutical companies.

Oscotec Swings to Cumulative Profit as Agios Deal and Leclaza Royalties Offset Wider Q3 Loss

https://finance.biggo.com/news/f923f0c3-a4f5-4470-9ada-10a49933b517
Oscotec reported a significant cumulative operating profit for the first nine months of 2026, reversing a prior-year loss, largely due to a 37.5 billion won upfront payment from Agios for Sevidoflenib and 24.598 billion won in Lazertinib milestones and royalties. This performance overshadowed a weaker third quarter, where revenue declined and the operating loss widened. The company is increasing R&D spending and aims for five out-licensing deals by 2034, with two already completed.

Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $47, Implies 48% Upside

https://www.tradingview.com/news/tradingview:3cf72c24be17f:0-agios-pharmaceuticals-inc-stock-12-month-price-target-raised-to-47-implies-48-upside/
Agios Pharmaceuticals, Inc. (AGIO) has seen its average 12-month price target raised from $45.38 to $47 by 7 analysts, with forecasts ranging from $32 to $74 per share. This updated target implies a potential upside of approximately 48% based on the November 12th closing price. The consensus rating among 10 covering analysts remains "Buy," with 7 "Buy" ratings and 3 "Hold" ratings.
Advertisement

Is Agios Pharmaceuticals (AGIO) Undervalued Following Stronger Q3 Results And Its FDA Review Update?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-undervalued-following-stronger
Agios Pharmaceuticals (AGIO) recently provided a third-quarter earnings update and news on its mitapivat regulatory review, showing a mixed performance with a 16.85% year-to-date gain but a 25.34% one-year decline. Analysts on Simply Wall St suggest the stock is 31% undervalued, with a fair value of $46.00 against a $31.76 close, primarily due to expectations for mitapivat's growth and pipeline assets. However, a high P/S ratio of 13.5x compared to an industry average of 10.3x indicates potential valuation risk if market sentiment shifts.

Weekly Recap: Q3 product revenue rises and FDA delays mitapivat review

https://www.tradingview.com/news/tradingview:ca2e7d70110cc:0-weekly-recap-q3-product-revenue-rises-and-fda-delays-mitapivat-review/
Agios Pharmaceuticals (AGIO) reported a significant rise in Q3 2026 product revenue to $55.4 million, though it posted a net loss of $65 million. The FDA has delayed its review of mitapivat for sickle cell disease to February 1, 2027, and Agios plans to cut over 100 R&D jobs by the end of 2026. The company also announced progress in its other clinical programs and positive data from the RISE UP trial for mitapivat.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-inc-nasdaqagio-third-quarter-results-j
Agios Pharmaceuticals (NASDAQ:AGIO) exceeded analyst expectations in its third-quarter results, with revenues of US$55m, beating estimates by 7.3%. Analysts are forecasting revenues of US$347.4m in 2027, a 147% improvement, and expect losses per share to narrow by 40% to US$3.75. The consensus price target remains at US$45.88, indicating the business is trading in line with expectations despite ongoing losses.

Truist cuts Agios Pharma stock price target on SCD concerns

https://www.investing.com/news/analyst-ratings/truist-cuts-agios-pharma-stock-price-target-on-scd-concerns-93CH-5005455
Truist Securities has lowered its price target for Agios Pharmaceuticals (NASDAQ:AGIO) to $35 from $37, while maintaining a Buy rating, citing concerns related to sickle cell disease (SCD) and competitive landscape discussions following the company's third-quarter 2026 earnings report. Despite an EPS miss, total mitapivat revenue exceeded estimates. Agios also announced significant R&D headcount reductions for 2027, aiming for non-GAAP profitability by 2028 amid rapid cash burn, although InvestingPro analysis suggests the stock is undervalued with more cash than debt.

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ...

https://sg.finance.yahoo.com/news/agios-pharmaceuticals-inc-agio-q3-230854809.html
Agios Pharmaceuticals Inc (AGIO) reported a significant revenue surge in Q3 2026, with total net revenue reaching $55.4 million, more than four times that of Q3 2025, driven largely by the AQVESME thalassemia launch. The company maintains a strong cash position of $907 million and targets non-GAAP profitability by 2028, despite a net loss of $65 million in Q3 2026 and an FDA PDUFA delay for its sickle cell disease sNDA.
Advertisement

Agios axes 100-plus R&D roles while awaiting FDA decision

https://www.biospace.com/job-trends/agios-axes-100-plus-r-d-roles-while-awaiting-fda-decision
Agios Pharmaceuticals is cutting over 35% of its R&D team, impacting more than 100 employees, after the FDA delayed its decision on the company's sickle cell disease candidate, mitapivat, until February 2027. This restructuring shifts the biopharma's focus to commercialization and late-stage rare hematology candidates, aiming for profitability by 2028 and incurring approximately $11 million in charges this year. The company's stock fell significantly following the FDA's decision to request more information on a potential safety protocol for mitapivat.

Is Agios Pharmaceuticals (AGIO) A Bargain Following Record Revenue And An FDA Review Delay?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-a-bargain-following-record-rev
Agios Pharmaceuticals recently experienced a significant share price drop after reporting record third-quarter revenue from mitapivat and a delayed FDA review for its sickle cell disease treatment, alongside an R&D restructuring. Despite a recent 9.91% single-day decline and an 11.07% drop over 30 days, the stock is still up 4.01% year-to-date, with a 3-year return of 33.73%. Analysts consider AGIO undervalued at $46.00 compared to its $28.27 share price, contingent on successful execution of its rare-disease commercial platform, but its current P/S ratio of 17.2x indicates valuation risk.

Agios Pharmaceuticals cutting over 100 R&D jobs as it shifts focus to commercial launches

https://www.bizjournals.com/boston/news/2026/11/05/agios-cutting-over-100-r-d-roles-in-2026.html
Agios Pharmaceuticals is reducing its research and development workforce by over 100 roles, representing more than a 35% cut. The Cambridge-based company is making this strategic shift to prioritize commercial launches and aims to achieve profitability by 2028. Agios is a commercial-stage company that develops medicines for patients with rare diseases.

What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:e20580cf0094b:0-what-agios-pharmaceuticals-agio-said-on-its-q3-earnings-call/
Agios Pharmaceuticals (AGIO) reported strong Q3 results, with total mitapivat net revenue reaching $55.4 million, primarily driven by the U.S. launch of its thalassemia drug, AQVESME. The company narrowed its net loss and aims for non-GAAP profitability by 2028, supported by R&D role reductions. The FDA extended its review for mitapivat in sickle cell disease to February 2027, with Agios preparing for a potential Risk Evaluation and Mitigation Strategy.

Agios to Cut Over 100 R&D Jobs in 2026 as It Preps for Sickle Cell Launch

https://finance.biggo.com/news/9a152226-5788-428c-b510-735736c8fbfa
Agios Pharmaceuticals plans to eliminate over 100 R&D jobs, more than 35% of its research workforce, by the end of 2026, primarily to reduce spending ahead of a potential U.S. launch of mitapivat for sickle cell disease. The FDA's decision on mitapivat in sickle cell disease has been delayed to February 1, 2027, but the company reported record quarterly revenue of $55.4 million for mitapivat in thalassemia. Despite the delay, Agios remains focused on profitability by 2028 and expanding its pipeline.
Advertisement

AGIO: Record mitapivat revenue and a delayed—but launch-ready—sickle cell opportunity define the quarter

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4475307:0-agio-record-mitapivat-revenue-and-a-delayed-but-launch-ready-sickle-cell-opportunity-define-the-quarter/
Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4 million, a more than fourfold increase year-over-year, primarily driven by AQVESME. The review for their sickle cell treatment has been delayed to February 1, 2027, due to an FDA REMS information request. Despite this, the company remains focused on launch readiness and its target of non-GAAP profitability by 2028.

Agios Pharmaceuticals Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62919907/agios-pharmaceuticals-q3-2026-earnings-call-transcript
Agios Pharmaceuticals reported record third-quarter product revenue of $55.4 million, a four-fold increase from the prior year, primarily driven by the U.S. launch of mitapivat in thalassemia. The company is preparing for the potential launch of mitapivat in sickle cell disease, with an FDA decision expected by February 2027, despite a recent request for additional safety data. Agios aims for non-GAAP profitability by 2028, supported by significant R&D headcount reductions and $907 million in cash reserves, while advancing its rare hematology pipeline.

Form 8K Agios Pharmaceuticals, Inc For: 5 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-agios-pharmaceuticals-inc-for-5-november-93CH-4933927
This article announces that Agios Pharmaceuticals, Inc. filed a Form 8K on November 5. The brief report from Investing.com highlights the filing for the company, which is identified by the stock symbol AGIO. The article is a straightforward notification without further details on the content of the Form 8K.

AGIOS PHARMACEUTICALS ($AGIO) Releases Q3 2026 Earnings

https://www.quiverquant.com/news/AGIOS+PHARMACEUTICALS+%28%24AGIO%29+Releases+Q3+2026+Earnings
AGIOS PHARMACEUTICALS ($AGIO) reported its Q3 2026 earnings, beating analyst estimates for both earnings per share and revenue. The company reported an EPS of -$1.09 against an estimated -$1.25, and revenue of $55.39 million against an estimated $54.27 million. The article also provides details on insider trading activity, hedge fund movements, congressional stock trading, and recent analyst price targets for AGIO.

What Agios Pharmaceuticals Bears Saw Before The Fall

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/what-agios-pharmaceuticals-bears-saw-before-the-fall
Agios Pharmaceuticals shareholders have experienced a 22.2% loss over the past year. The article explores the contrasting bullish and bearish arguments surrounding the company, focusing on the expansion of its drug PYRUKYND, revenue growth, and regulatory pressures. While PYRUKYND's European approval and increased revenue support the optimistic view, the company's net loss still raises questions about profitability.
Advertisement

Agios reveals promising long-term data for mitapivat in sickle cell disease and AG-236 in polycythemia vera at ASH 2026.

https://pluang.com/en/news-feed/agios-unggulkan-portofolio-hematologi-jarang-data-klinis-baru-ash-2026
Agios Pharmaceuticals presented new clinical data at ASH 2026, showing that mitapivat offers durable hemoglobin improvements for up to two years in sickle cell disease patients and provides additional kidney and heart benefits. The company also released initial human data for AG-236, suggesting a potential every-six-month dosing for polycythemia vera. These findings underscore the potential of Agios' rare hematology treatments to significantly improve care for patients with critical unmet medical needs.

What Agios Pharmaceuticals (AGIO)'s FDA Review Delay Means For Shareholders

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/what-agios-pharmaceuticals-agios-fda-review-delay-means-for/amp
Agios Pharmaceuticals announced that the FDA extended the PDUFA goal date for mitapivat's sickle cell disease sNDA to February 1, 2027, classifying updated safety information as a major amendment. This delay, while operational, highlights ongoing regulatory and commercial timing risks for investors. The company's investment narrative now focuses on its ability to address these requirements and build its commercial base.

FDA extends mitapivat sickle cell disease sNDA review deadline to February 2027

https://allsci.com/news/biotech/mitapivat-sickle-cell-fda-extends-disease-snda/
The US FDA has extended its review deadline for Agios Pharmaceuticals' mitapivat, an oral pyruvate kinase activator for sickle cell disease, from November 1, 2026, to February 1, 2027. This three-month extension allows the agency to evaluate additional safety information submitted by Agios, classified as a major amendment, to determine if a Risk Evaluation and Mitigation Strategy (REMS) is required. Despite a boxed warning for liver injury with mitapivat in thalassemia, Agios asserts no similar severe liver injury has been reported in sickle cell patients, maintaining its positive benefit-risk assessment.

Weekly Recap: FDA extends mitapivat review and analyst starts Buy coverage

https://www.tradingview.com/news/tradingview:b54cc11ae7d91:0-weekly-recap-fda-extends-mitapivat-review-and-analyst-starts-buy-coverage/
Agios Pharmaceuticals (AGIO) is facing a three-month extension for the FDA review of mitapivat for sickle cell disease, with a new decision date of February 1, 2027. Despite this, HC Wainwright & Co. has initiated coverage of AGIO with a Buy rating and a $55 price target. The extension is attributed to ongoing labeling discussions.

H.C. Wainwright Initiates Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55

https://www.moomoo.com/news/post/1002842003/hc-wainwright-initiates-agios-pharmaceuticals-agious-with-buy-rating-announces
H.C. Wainwright has initiated coverage on Agios Pharmaceuticals (AGIO.US) with a "Buy" rating. The firm has set a target price of $55 for the company's stock, indicating a positive outlook for its future performance.
Advertisement

FDA Extends Agios’ Mitapivat Review for Sickle Cell Disease by Three Months

https://www.tokenpost.com/news/regulation/44812
The FDA has extended its review of Agios Pharmaceuticals' supplemental New Drug Application for mitapivat in sickle cell disease by three months. The new PDUFA goal date is February 1, 2027, moved from the previous November 1, 2026. The application, which seeks approval for mitapivat (branded PYRUKYND), was granted Priority Review by the FDA in July.

Agios Pharmaceuticals Announces FDA Extends Review of Mitapivat sNDA for Sickle Cell Disease to February 1, 2027

https://www.quiverquant.com/news/Agios+Pharmaceuticals+Announces+FDA+Extends+Review+of+Mitapivat+sNDA+for+Sickle+Cell+Disease+to+February+1%2C+2027
Agios Pharmaceuticals announced that the FDA has extended the PDUFA goal date for its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease to February 1, 2027. This three-month extension is due to the FDA classifying Agios' response to an information request as a major amendment, seeking further evaluation for a potential Risk Evaluation and Mitigation Strategy (REMS). Despite the delay, Agios remains confident in mitapivat's potential, citing strong clinical data and no new cases of hepatocellular injury, while continuing labeling discussions with the FDA.

Citi Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $52

https://www.moomoo.com/news/post/1002648451/citi-maintains-agios-pharmaceuticals-agious-with-buy-rating-maintains-target
Citi has reiterated its Buy rating on Agios Pharmaceuticals (AGIO.US) and maintained its target price at $52. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.

HC Wainwright & Co. assumes coverage of Agios Pharmaceuticals at Buy, sets price target at $55

https://www.tradingview.com/news/tradingview:de85557273c59:0-hc-wainwright-co-assumes-coverage-of-agios-pharmaceuticals-at-buy-sets-price-target-at-55/
HC Wainwright & Co. initiated coverage on Agios Pharmaceuticals with a Buy rating and set a price target of $55. This target suggests a potential upside of 44.3% from the stock's closing price of $38.12 on October 28. Investors can find more detailed analyst ratings and price target data on TradingView's platform.

After a $25.01 option exercise, Sarah Gheuens sells 7,866 Agios Pharmaceuticals (AGIO) shares.

https://www.stocktitan.net/sec-filings/AGIO/form-4-agios-pharmaceuticals-inc-insider-trading-activity-7d48e1d98670.html
Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, exercised options for 7,866 shares at $25.01 each and subsequently sold all 7,866 shares at a weighted average price of $37.69 per share under a Rule 10b5-1 trading plan. The sale resulted in approximate gross proceeds of $296,000 and a pre-tax spread of $100,000. Following the transactions, Gheuens retained options covering 16,275 shares expiring in 2033 and directly held 54,645 common shares.
Advertisement

A 7,866-share sale is planned by Agios (NASDAQ: AGIO) officer Sarah Gheuens.

https://www.stocktitan.net/sec-filings/AGIO/144-agios-pharmaceuticals-inc-sec-filing-cc8f1f32ddb6.html
Agios Pharmaceuticals, Inc. officer Sarah Gheuens has reported a planned sale of 7,866 common shares, valued at approximately $296,467.97, with an anticipated sale date of October 26, 2026. These shares were acquired through a stock option exercise. The filing also details three previous common share sales by Gheuens in August and October 2026.

Form 144 AGIOS PHARMACEUTICALS For: 21 October By Investing.com

https://za.investing.com/news/stock-market-news/form-144-agios-pharmaceuticals-for-21-october-93CH-4517910
This article from Investing.com announces the filing of Form 144 for Agios Pharmaceuticals (AGIO) on October 21. It briefly mentions the company's stock performance and includes a Reuters copyright, but provides no further details about the Form 144 filing itself.

Agios Pharmaceuticals, Inc. Estimates – NASDAQ:AGIO

https://www.tradingview.com/symbols/NASDAQ-AGIO/financials-estimates/
This article provides an overview of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) financial data and analyst estimates available on TradingView. It highlights sections for exploring reported financial data, comparing actual results with estimates, and visualizing trends across income statements, balance sheets, and cash flow statements. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.

Form 144 AGIOS PHARMACEUTICALS For: 22 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-agios-pharmaceuticals-for-22-october-93CH-4898077
This article from Investing.com announces the filing of Form 144 for Agios Pharmaceuticals (AGIO) on October 22nd. Form 144 indicates an intent to sell restricted or controlled securities, typically by insiders. The brief news update is accompanied by market data and other related articles on the Investing.com platform.

A 500-share sale is proposed by Agios (NASDAQ: AGIO) officer Sarah Gheuens.

https://www.stocktitan.net/sec-filings/AGIO/144-agios-pharmaceuticals-inc-sec-filing-003d9f4a5da0.html
Agios Pharmaceuticals, Inc. officer Sarah Gheuens has proposed the sale of 500 common shares, valued at $18,760.00, with an approximate sale date of October 22, 2026. These shares were acquired through a stock option exercise on the same date. The SEC filing also details two prior sales by Gheuens, including 30,000 shares on August 4, 2026, and 1,489 shares on October 21, 2026.
Advertisement

Form 144 AGIOS PHARMACEUTICALS For: 21 October By Investing.com

https://au.investing.com/news/stock-market-news/form-144-agios-pharmaceuticals-for-21-october-93CH-4705942
This article from Investing.com announces the filing of Form 144 for Agios Pharmaceuticals (AGIO) on October 21. Form 144 relates to the proposed sale of restricted securities. The article provides the title and date of the filing without further details.

Form 144 AGIOS PHARMACEUTICALS For: 21 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-agios-pharmaceuticals-for-21-october-93CH-2749792
Investing.com reports on the filing of Form 144 for Agios Pharmaceuticals (AGIO) on October 21, 2026. The article notes a 1.67% decrease in AGIO's stock price and provides financial market data and news updates from various sectors.

An Agios (NASDAQ: AGIO) officer proposes selling about $55.9K in shares acquired by exercising options.

https://www.stocktitan.net/sec-filings/AGIO/144-agios-pharmaceuticals-inc-sec-filing-8ddcc6263b6c.html
Agios Pharmaceuticals officer Sarah Gheuens has proposed selling 1,489 common shares, valued at approximately $55,881.28, which were acquired through a stock option exercise. The proposed sale date is October 21, 2026. This filing also notes a previous sale of 30,000 common shares by Gheuens on August 4, 2026, for $914,283.00.

Is Agios Pharmaceuticals (AGIO) Undervalued On Hopes For A Mitapivat FDA Decision?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/is-agios-pharmaceuticals-agio-undervalued-on-hopes-for-a-mit
Agios Pharmaceuticals (AGIO) is under scrutiny as investors anticipate the FDA's accelerated approval decision for Mitapivat in sickle cell disease. While a bullish narrative suggests AGIO is 21% undervalued with a fair value of $44.00, driven by future cash flow expectations and potential market expansion for PYRUKYND, an alternative view using a sales multiple lens indicates significant valuation risk, with a P/S ratio of 19x compared to the industry average of 11.2x. The market appears divided between optimism for Mitapivat's success and concerns over high spending and concentration risks.

Why Did Agios Pharmaceuticals (NASDAQ:AGIO) Rise 7.41% Before a November 1 FDA Decision on Mitapivat in Sickle Cell Disease?

https://kalkine.ca/news/general-news/why-did-agios-pharmaceuticals-nasdaqagio-rise-741-before-a-november-1-fda-decision-on-mitapivat-in-sickle-cell-disease
Agios Pharmaceuticals (NASDAQ:AGIO) saw its stock rise 7.41% ahead of a November 1 FDA decision on its supplemental application for mitapivat in sickle cell disease. The FDA accepted the application under Priority Review, and the company's RISE UP Phase 3 trial met its primary hemoglobin endpoint. Investors are focusing on this upcoming FDA decision, along with the launch of AQVESME and any potential accelerated approval conditions.
Advertisement

GSK, INO, AGIO And Sun Pharma Await Key FDA Rulings In October That Could Shape Their Drug Pipelines

https://stocktwits.com/news-articles/markets/equity/gsk-inovio-agios-sun-pharma-fda-decision-calendar-october/cZx8jI5RBML
The FDA is set to make key decisions on several experimental treatments in October and early November. These include GSK's hepatitis B treatment, Inovio's therapy for recurrent respiratory papillomatosis, Agios's Mitapivat for sickle cell disease, and Sun Pharmaceutical Industries' Ilumya for psoriatic arthritis, with these rulings potentially impacting the drug pipelines and stock performance of the respective companies.

(AGIO) and the Role of Price-Sensitive Allocations

https://news.stocktradersdaily.com/news_release/78/AGIO_and_the_Role_of_Price-Sensitive_Allocations_101026091401_1791638041.html
This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting a neutral near-term sentiment that could moderate mid-term weakness. It identifies resistance testing, potential support, and an exceptional short-setup opportunity with a 68.3:1 risk-reward ratio. The analysis includes AI-generated institutional trading strategies and multi-timeframe signal analysis for different risk profiles.

Agios Pharma (AGIO) Gets a Hold from RBC Capital

https://www.theglobeandmail.com/investing/markets/stocks/AGIO/pressreleases/5521370/agios-pharma-agio-gets-a-hold-from-rbc-capital/
RBC Capital analyst Luca Issi has maintained a Hold rating on Agios Pharma (AGIO) with a price target of $32.00, while the analyst consensus is a Moderate Buy with an average target of $43.00. The company reported a quarterly revenue of $44.75 million and a GAAP net loss of $100.7 million for the quarter ending June 30. Other analysts have recently adjusted their price targets for Agios Pharmaceuticals.

Agios Pharmaceuticals, Inc. (AGIO) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/AGIO/
This Yahoo Finance page provides a detailed financial overview of Agios Pharmaceuticals, Inc. (AGIO), including its stock price, historical data, key financial metrics, and analyst insights. It covers the company's biopharmaceutical focus on cellular metabolism, its lead product PYRUKYND for various hemolytic anemias, and other pipeline developments. The page also presents performance data compared to the S&P 500 and recent earnings trends.

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

https://www.marketscreener.com/news/agios-to-host-third-quarter-2026-financial-results-conference-call-and-webcast-on-november-5-at-8-00-ce785dded080f121
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced it will host a conference call and live webcast on November 5, 2026, at 8:00 a.m. ET to discuss its third-quarter 2026 financial results and provide business updates. The webcast will be available on the Investors section of the company's website under "Events & Presentations," with a replay accessible approximately two hours after the live event. Agios is a commercial-stage biopharmaceutical company focused on developing innovative medicines for rare diseases.
Advertisement

Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $37

https://www.moomoo.com/news/post/1000696015/truist-financial-maintains-agios-pharmaceuticals-agious-with-buy-rating-announces
Truist Financial has reiterated its Buy rating on Agios Pharmaceuticals (AGIO.US) and set a target price of $37. This indicates a positive outlook from the financial institution regarding the company's stock performance.

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

https://es.tradingview.com/news/zacks:6b784aceb094b:0-agio-stock-sinks-29-in-three-months-here-s-what-you-need-to-know/
Shares of Agios Pharmaceuticals (AGIO) have dropped 29% in the last three months despite strong sales of its drug mitapivat. This decline is largely due to setbacks with its pipeline candidate tebapivat, which failed to show sufficient differentiation and was discontinued for all indications, narrowing the company's growth prospects. Agios is now increasingly reliant on mitapivat and its expansion into new indications, facing intensifying competition in the sickle cell disease market.

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

https://www.tradingview.com/news/zacks:6b784aceb094b:0-agio-stock-sinks-29-in-three-months-here-s-what-you-need-to-know/
Agios Pharmaceuticals (AGIO) shares have dropped 29% in three months despite strong mitapivat sales, primarily due to setbacks with its pipeline candidate, tebapivat. The failure of tebapivat in both LR-MDS and sickle cell disease has narrowed Agios' pipeline, increasing its reliance on mitapivat. While mitapivat sales are growing, intensified competition in the sickle cell disease market, particularly from Novo Nordisk's etavopivat, poses a challenge to Agios' long-term growth and diversification efforts.

Why Is AGIO Stock Falling Today?

https://stocktwits.com/news-articles/markets/equity/why-is-agio-stock-falling-today/cZZSfDCR7va
Agios Pharmaceuticals (AGIO) shares dropped over 4% after the company announced it would stop developing its sickle cell disease therapy, Tebapivat, due to disappointing Phase 2 trial results. The drug's profile was not sufficiently differentiated from existing treatments, leading Agios to pivot its focus to Mitapivat, for which a key regulatory decision is expected by November 1, 2026. Despite the setback, retail sentiment for AGIO has shifted to 'neutral' from 'bearish' with high message volumes, and the stock has gained over 39% year-to-date.

Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

https://ca.finance.yahoo.com/news/agios-growth-story-hinges-mitapivats-132200618.html
Agios Pharmaceuticals is heavily relying on its lead therapy, mitapivat, for commercial growth as it expands into multiple blood disorders, including pyruvate kinase deficiency and thalassemia, and seeks approval for sickle cell disease. Despite strong early commercial performance for Pyrukynd and Aqvesme, the company faces significant competition from other pharmaceutical giants like Novo Nordisk and Bristol Myers Squibb in its target markets. The discontinuation of a next-generation growth driver, tebapivat, further underscores mitapivat's critical role in Agios's near-to-medium-term success.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement